A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC

por Melosky, Barbara L., Lim, Howard John, Davies, Janine Marie, Gill, Sharlene, Kollmannsberger, Christian K., Ho, Maria Yi, Vandt, Solomon A., Renouf, Daniel John
Publicado 2018

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade

por Lavoie, Jean-Michel, Baichoo, Priya, Chavez, Elizabeth, Nappi, Lucia, Khalaf, Daniel, Kollmannsberger, Christian K., Chi, Kim N., Weng, Andrew, Steidl, Christian, Eigl, Bernhard J., Nissen, Michael
Publicado 2022

Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways

por Lavoie, Jean-Michel, Csizmok, Veronika, Williamson, Laura M., Culibrk, Luka, Wang, Gang, Marra, Marco A., Laskin, Janessa, Jones, Steven J.M., Renouf, Daniel J., Kollmannsberger, Christian K.
Publicado 2022

TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors

por Bacon, Jack V W, Giannatempo, Patrizia, Cataldo, Giovanna, Fazli, Ladan, Saxena, Neetu, Ozgun, Guliz, Soleimani, Maryam, Chi, Kim, Nichols, Craig, Necchi, Andrea, Wyatt, Alexander W, Kollmannsberger, Christian K, Nappi, Lucia
Publicado 2022

The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey

por Al-Ezzi, Esmail M., Zahralliyali, Amer, Hansen, Aaron R., Hamilton, Robert J., Crump, Michael, Kuruvilla, John, Wood, Lori, Nappi, Lucia, Kollmannsberger, Christian K., North, Scott A., Winquist, Eric, Soulières, Denis, Hotte, Sebastien J., Jiang, Di Maria
Publicado 2023

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

por Chiu, Joanne W., Hotte, Sebastien J., Kollmannsberger, Christian K., Renouf, Daniel J., Cescon, David W., Hedley, David, Chow, Sue, Moscow, Jeffrey, Chen, Zhuo, Perry, Meghan, Diaz-Padilla, Ivan, Tan, David, Hirte, Hal, McWhirter, Elaine, Chen, Helen, Siu, Lillian L., Bedard, Philippe L.
Publicado 2015

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

por Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J
Publicado 2020

Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

por Zazuli, Zulfan, Otten, Leila S., Drögemöller, Britt I., Medeiros, Mara, Monzon, Jose G., Wright, Galen E. B., Kollmannsberger, Christian K., Bedard, Philippe L., Chen, Zhuo, Gelmon, Karen A., McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Ross, Colin J. D., Liu, Geoffrey, Carleton, Bruce C., Maitland-van der Zee, Anke H.
Publicado 2019

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

por Motzer, Robert J., McDermott, David F., Escudier, Bernard, Burotto, Mauricio, Choueiri, Toni K., Hammers, Hans J., Barthélémy, Philippe, Plimack, Elizabeth R., Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Gurney, Howard, Kollmannsberger, Christian K., Grimm, Marc‐Oliver, Barrios, Carlos, Tomita, Yoshihiko, Castellano, Daniel, Grünwald, Viktor, Rini, Brian I., McHenry, M. Brent, Lee, Chung‐Wei, McCarthy, Jennifer, Ejzykowicz, Flavia, Tannir, Nizar M.
Publicado 2022

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random...

por Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Publicado 2021